Selectra

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Selectra

What is Selectra?

Selectra is a medication that belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRIs). It is primarily used in the treatment of various mental health conditions, focusing on stabilizing mood and emotional response.

Mechanism of Action

The active ingredient in Selectra works by increasing the levels of serotonin in the brain. Serotonin is a neurotransmitter, a chemical messenger that carries signals between brain cells. It is often referred to as a "feel-good" chemical because of its role in regulating mood, sleep, and anxiety. By preventing the reabsorption (reuptake) of serotonin into neurons, the medication makes more of this chemical available to improve the transmission of messages between neurons, which can help alleviate symptoms of depression and anxiety.

Therapeutic Uses

Selectra is commonly prescribed for several psychological conditions, including:

  • Major Depressive Disorder: Helping to lift persistent low mood and restore interest in daily activities.
  • Panic Disorder: Reducing the frequency and intensity of panic attacks.
  • Social Anxiety Disorder: Assisting individuals who experience significant distress in social situations.
  • Generalized Anxiety Disorder: Managing chronic, excessive worry that interferes with daily life.
  • Obsessive-Compulsive Disorder (OCD): Helping to reduce repetitive thoughts and behaviors.

Nature of the Medication

As an SSRI, Selectra is designed for long-term management rather than immediate relief. It typically takes several weeks of consistent use for the full therapeutic effects to be felt. The medication is intended to support emotional balance and is often used as part of a comprehensive treatment plan that may include psychological therapy and lifestyle adjustments.

Regulatory References

  1. Sertraline - StatPearls - NCBI Bookshelf

What side effects are possible with Selectra?

Possible side effects and safety information

The official safety profile for Selectra, which contains Sertraline, is structured by classifying documented adverse reactions based on their frequency and the body system affected, as defined by regulatory authorities.

Adverse reactions are classified into categories such as Very Common, Common, and Uncommon.


Key Adverse Reaction Classifications

Classification Examples of Effects (SOC Group)
Very Common (ge 10%) Nausea, Dry Mouth, Insomnia, Dizziness, Ejaculation Failure (Gastrointestinal, Nervous System, Psychiatric, Reproductive Systems)
Common (1% to 10%) Diarrhea/Loose stools, Tremor, Decreased Appetite, Hyperhidrosis (Increased Sweating), Somnolence (Gastrointestinal, Nervous System, Metabolism, General Disorders)

Serious and Clinically Significant Safety Risks

The regulatory label documents the potential for serious reactions and safety concerns. There is a documented risk of Suicidal Thoughts and Behaviors (STB), particularly in children, adolescents, and young adults when treatment is first initiated. The possibility of Serotonin Syndrome or Neuroleptic Malignant Syndrome-like reactions is a recognized concern, especially with concurrent use of other serotonergic medicines.

Furthermore, the label notes a potential for Hyponatremia (low blood sodium), which is of particular consideration in older adults. The medicine is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of Serotonin Syndrome. Safety considerations exist for patients with hepatic impairment, as clearance of Sertraline is reduced in these individuals.

Regarding time-related patterns, the risk of STB may be heightened when first starting treatment, while certain effects like sexual dysfunction may be dose-dependent and potentially transient with continued use.

Overdose and Emergency Response

The official regulatory profile for Selectra (Sertraline) overdose documents specific clinical and physiological manifestations, necessitating immediate professional care based on established emergency protocols.

Overdose Scope: Officially Documented Manifestations Regulatory Statement
Documented Signs Officially listed manifestations include Central Nervous System effects such as somnolence, confusion, and agitation, alongside physical signs like tremor, shivering, tachycardia (rapid heart rate), and gastrointestinal symptoms like nausea and diarrhea.
Severe Outcomes The risk of severe, potentially life-threatening outcomes is documented, including Serotonin Syndrome, seizures, coma, and cardiac abnormalities such as QTc prolongation and Torsade de Pointes.
Exposure-Related Factors Increased risk of fatality is reported when the drug is taken in combination with other substances and/or alcohol (mixed overdose).
Emergency Response and Management Regulatory Statement
Immediate Action Required Seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if the affected individual has collapsed, experienced a seizure, or cannot be awakened.
Antidote and Treatment No specific antidote to Sertraline is known. Management is defined as general symptomatic and supportive measures, which involves establishing an airway and continuous cardiac (ECG) monitoring. Induction of emesis is not recommended.

Official overdose statements: Overdose may escalate from documented signs like somnolence and tremor to potentially life-threatening outcomes, including Serotonin Syndrome, seizures, and coma. Given the lack of a known antidote, the regulatory requirement is to seek immediate medical intervention for supportive treatment and monitoring.

Therapeutic Uses of Selectra

What Selectra Treats: Main Uses and Benefits

Selectra (Sertraline) is commonly used across several therapeutic domains to provide symptomatic relief and supports patients during episodes of heightened discomfort. It is applied in clinical settings marked by heightened distress and when symptoms create noticeable interference with daily stability, and is aligned with therapeutic domains where short-term symptom management is appropriate.

It may assist with addressing symptom clusters that interfere with daily functioning, commonly used across conditions such as Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD), and Premenstrual Dysphoric Disorder (PMDD). It is used to help address pronounced symptoms like persistent low mood, severe worry, intense fear, and the recurrence of disruptive panic attacks.

Applied in addressing these challenging manifestations, the medicine contributes to easing the overall symptom load and may assist with maintaining a sense of stability when symptoms are more noticeable.


Quick Fact: Relief for Key Symptom Clusters
Selectra is relevant for managing symptoms that interfere with daily comfort, and may assist with easing manifestations like intrusive thoughts (obsessions) and severe mood instability in cyclical conditions.

Selectra is primarily applied in settings where patients experience conditions characterized by periods of heightened symptoms, and it may contribute to maintaining functional stability.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Selectra — Official Regulatory Information


Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed Adults (18 years and older) for all approved indications. Children and adolescents (6-17 years) only for Obsessive-Compulsive Disorder (OCD).
Populations for whom use is not recommended Patients with Severe Hepatic Impairment. Breastfeeding patients, unless the benefit to the mother is determined to outweigh the risk to the infant.
Populations for whom use is contraindicated Patients taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping one. Patients taking Pimozide. Patients with known hypersensitivity to sertraline or product excipients.
Age-related eligibility rules Safety and effectiveness are not established in pediatric patients under 6 years. Use in adolescents is not established for non-OCD indications.
Condition-specific eligibility rules Use in mild/chronic hepatic impairment requires caution. No dosage adjustment is typically required for renal impairment.
Pregnancy and lactation eligibility status Third Trimester use may increase risk for persistent pulmonary hypertension and symptoms of poor adaptation in the neonate. Lactation use is not recommended unless essential.

Eligibility Classifications (High-Level)

Category Official Regulatory Classification
Eligibility severity classification Contraindicated (Absolute prohibition); Not Recommended (Avoid/Benefit must outweigh risk); Use Not Established (Lack of data); Use with Caution (Requires special consideration).
Eligibility-context constraints Time constraint (14-day washout period with MAOIs); Age constraint (6-17 years limited to OCD); Organ function constraint (Severe Hepatic Impairment).

Connection to the Overall Eligibility Profile

Regulatory documents strictly define eligibility through absolute contraindications, primarily for patients taking MAOIs or Pimozide. Beyond these prohibitions, eligibility is structured by population status: use is limited to OCD for the pediatric age range (6-17) and requires caution for older adults and individuals with pre-existing conditions like a history of mania or severe liver impairment. This structure establishes clear, label-based boundaries for the patient populations permitted, restricted, or prohibited from using the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes documented, clinically significant interactions for Selectra (sertraline) with other medicinal products, product classes, and substances, as mandated by official regulatory documentation. This information is intended for healthcare professionals and patients to understand required constraints on use.

Contraindicated Combinations

The following combinations must not be used:

  • Monoamine Oxidase Inhibitors (MAOIs): Concurrent use with MAOIs, including linezolid and intravenous methylene blue, is strictly prohibited due to the risk of serious Serotonin Syndrome. A mandatory wash-out period of at least 14 days is required when switching between sertraline and an MAOI.
  • Pimozide: Concomitant use with the antipsychotic agent pimozide is prohibited.
  • Disulfiram: The sertraline oral solution formulation must not be used with disulfiram.

Interactions Requiring Precaution or Monitoring

  • Other Serotonergic Drugs: Co-administration with other serotonergic agents (e.g., triptans, fentanyl, lithium, tramadol) increases the risk of Serotonin Syndrome and requires close clinical monitoring.
  • Increased Bleeding Risk: Use with antiplatelet drugs (e.g., aspirin, NSAIDs) and anticoagulants (e.g., Warfarin) increases the risk of bleeding. If co-administered with Warfarin, coagulation status must be closely monitored, and dosage adjustments may be necessary.
  • CYP2D6 Substrates: Sertraline can inhibit the CYP2D6 enzyme, which may increase the systemic exposure of drugs primarily metabolized by this pathway, requiring potential dosage reduction of the co-administered drug.
  • Food: Food increases the absorption of sertraline, leading to higher peak plasma concentrations.

Mechanism of Action

The mechanism of Selectra (Sertraline) involves a sequence of events centered on defined neurotransmitter systems and cellular adaptation.

The primary molecular interaction is the selective blockade of the Serotonin Transporter (SERT). By binding to SERT, the drug inhibits the reuptake of serotonin (5-HT) from the synaptic cleft, immediately increasing the concentration and persistence of this neurotransmitter. This action establishes a sustained, elevated level of serotonergic signaling.

The full physiological action requires an adaptive cascade that follows the initial molecular action. The early rise in 5-HT activates inhibitory presynaptic autoreceptors, which must undergo a period of desensitization and down-regulation over several weeks. This adaptive change is mandatory to overcome the initial inhibitory feedback, allowing the enhanced 5-HT signaling to drive necessary neuroplastic changes in neural circuits in the limbic and associated systems, which establishes a more consistent pattern of serotonergic transmission.

A distinct component of the mechanism is the binding of Sertraline to the Sigma-1 (sigma1) receptor. While the SERT block is the primary mechanism, this secondary interaction engages a non-monoaminergic pathway, further shaping the functional consequences on CNS activity.

Dosage and Administration Information

Administration and General Use Principles

Selectra (Sertraline) is approved strictly for oral administration as a film-coated tablet, capsule, or oral solution concentrate, and is taken once daily. The regimen is standardized, beginning with a condition-specific initial dose of 25 mg or 50 mg. Tablets may be administered with or without food and can be taken in the morning or evening.


Dosing and Schedule Protocol

For most uses, the starting dose is 50 mg per day. However, certain conditions may require a starting dose of 25 mg per day for the first week. Dose adjustments must be made slowly, in increments of 25 mg to 50 mg, no more frequently than once per week, toward the standard adult maximum of 200 mg daily. This schedule establishes a methodical approach to reaching the appropriate maintenance dose.


Special Administration and Tapering

The oral solution concentrate requires immediate dilution with specified liquids (such as water, ginger ale, or certain fruit juices) prior to consumption. Additionally, specialized forms, such as certain capsules, must be swallowed whole and are not indicated for use at the start of treatment. For specific populations, standard protocols require dose modification: the starting and maximum daily dose must be halved for patients with mild hepatic impairment. When concluding treatment, clinical guidance requires a gradual dose reduction (tapering) rather than abrupt cessation.

Recent Clinical Evidence

Selectra: Recent Clinical Evidence

Selectra (known generically as sertraline) is a medication classified as a selective serotonin reuptake inhibitor (SSRI). It is approved for the treatment of Major Depressive Disorder (MDD) and various anxiety-related conditions, including Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), and Social Anxiety Disorder.

Efficacy and Symptom Improvement

Recent meta-analyses and large-scale randomized controlled trials (RCTs) examining the use of Selectra in primary care populations have provided a nuanced understanding of its effects:

Condition Studied Key Research Finding Timeframe for Effects
Depressive Symptoms Studies indicate the drug's effect on core depressive symptoms (e.g., low mood) may become measurable after approximately 12 weeks of treatment. Effects often observed after 12 weeks.
Anxiety Symptoms Research suggests Selectra may exert an earlier measurable influence on generalized anxiety symptoms (e.g., nervousness, restlessness). Improvements may be detected as early as 2 to 6 weeks.
Comparison to Other SSRIs Meta-analyses often suggest the efficacy of Selectra is comparable to that of other first-line SSRIs in the acute-phase treatment of MDD. Some data indicates it may be slightly better tolerated than certain older-generation antidepressants.

Additional Areas of Research

Ongoing clinical research continues to explore Selectra's full profile, including its use in treating Premenstrual Dysphoric Disorder (PMDD) and its potential effects on inflammatory biomarkers associated with depression. This evolving body of evidence helps healthcare professionals determine suitability for various patient needs.

Key Studies & References

  1. Sertraline: MedlinePlus Drug Information (Authoritative overview of uses)

Frequently Asked Questions (FAQ)

Common questions about Selectra (FAQ)

Q: How long does it usually take for Selectra to start working?

A: Clinical studies and official information provide timeframes for when measurable effects of Selectra may be observed. Effects on core depressive symptoms may be noted after approximately 12 weeks of treatment. However, regulatory research suggests that an earlier measurable influence on generalized anxiety symptoms may be detected within 2 to 6 weeks.


Q: Can Selectra help with anxiety in addition to depression?

A: Yes, regulatory documents confirm that Selectra is approved for treating several anxiety-related conditions. These approved uses include Panic Disorder, Post-Traumatic Stress Disorder (PTSD), and Social Anxiety Disorder, in addition to its primary use for Major Depressive Disorder.


Q: What's the difference between Selectra and other common SSRIs?

A: Clinical meta-analyses often suggest that the observed efficacy of Selectra is generally similar to that of other first-line SSRIs (Selective Serotonin Reuptake Inhibitors) during the acute phase of treatment. Some data indicates that its safety profile may demonstrate favorable tolerability compared to certain older-generation antidepressants, according to meta-analyses.


Q: Do you always have to take Selectra with food?

A: No, the film-coated tablets can be administered with or without food, according to official product information. However, it is noted that taking the medication with food increases its absorption into the body. Understanding this absorption difference is part of the clinical considerations for treatment.


Q: What happens if I miss a dose of Selectra?

A: General product guidance suggests that if a dose is missed, the patient typically skips the missed dose and continues with the next scheduled dose at the usual time the following day. Patients are cautioned to not take two doses at once to compensate for a forgotten dose.


Q: Why do some people need to take Selectra for a long time?

A: Antidepressant treatment is often continued for a sustained period beyond the initial relief of symptoms. This approach is recommended as a maintenance phase and is intended to help reduce the risk of symptom recurrence following initial clinical recovery.


Q: Can Selectra affect my ability to drive or operate machinery?

A: Yes, according to official product information, Selectra may impair the mental or physical abilities needed for potentially hazardous tasks. Caution is generally advised; individuals should be aware of their response to the medication before engaging in tasks such as driving a car or operating machinery.


Q: Does Selectra have a generic version?

A: Yes. The active ingredient in Selectra is Sertraline (sertraline hydrochloride), and this compound is widely available as a generic medicine.


Q: Are there different strengths or forms of Selectra available?

A: Yes. Selectra (Sertraline) is typically available as film-coated tablets in multiple strengths, such as 25 mg, 50 mg, and 100 mg. The medication is also available in other formulations, including an oral solution concentrate, as noted in official sources.


Q: What is the half-life of Selectra in the body?

A: The half-life refers to the time required for the amount of medication in the bloodstream to decrease by half. According to regulatory pharmacokinetics data, the average terminal elimination half-life of the active ingredient, Sertraline, in adults is approximately 26 to 27 hours.


Q: How is Selectra eliminated from the body?

A: Selectra is extensively metabolized (broken down) primarily in the liver. The resulting compounds are then removed from the body and recovered in approximately equal amounts in the urine and feces.


Q: Is it common to feel tired or dizzy when first starting Selectra?

A: Yes, dizziness and tiredness are common experiences when first starting this medication. Official safety information lists dizziness as a Very Common side effect (occurring in many patients) and somnolence (drowsiness/tiredness) as a Common side effect (occurring in some patients).


Q: What are some serious side effects of Selectra to watch out for?

A: Regulatory warnings highlight the potential for serious reactions and safety risks. These include a documented risk of Suicidal Thoughts and Behaviors (STB), particularly when starting treatment, as well as the potential for Serotonin Syndrome and Hyponatremia (a serious drop in blood sodium levels).


Q: Can Selectra interact with birth control pills?

A: The official regulatory label does not specifically name oral contraceptives, but it notes that Selectra can affect the CYP2D6 enzyme, which is involved in metabolizing many other drugs. A healthcare provider can offer guidance regarding specific enzyme-related concerns that may be relevant to co-administration.


Q: Is it safe to drink alcohol while on Selectra?

A: Official guidance advises avoiding or limiting the consumption of alcohol while taking Selectra. The combination may enhance side effects such as dizziness, drowsiness, reduced concentration, and confusion.


Q: Is Selectra known to cause weight gain?

A: Official adverse reaction data lists Decreased Appetite as a Common side effect. However, the label does note that changes in weight, including both weight loss and weight gain, have been observed in long-term clinical trials across different groups of patients.


Q: Does taking Selectra impact sexual function?

A: Yes, the regulatory label documents that the medication can impact sexual function. Specifically, ejaculation failure is listed as a Very Common side effect in men, and other forms of sexual dysfunction, such as decreased libido, are also reported in official sources.


Q: Are there any dietary restrictions while taking Selectra?

A: Yes. Official information advises that patients should avoid taking Selectra with grapefruit or grapefruit juice. This avoidance is recommended because grapefruit consumption can lead to higher blood levels of the medication, potentially increasing the chance of side effects.


Q: Do I need regular blood tests while taking Selectra?

A: Regulatory guidelines require close monitoring of coagulation status (which involves blood tests) if Selectra is taken with blood thinners like Warfarin. Additionally, monitoring of serum sodium levels is often considered, particularly for older adults, due to the recognized risk of Hyponatremia.


Q: Can Selectra affect my blood pressure?

A: The most relevant official safety concern is the documented risk of Hyponatremia (low blood sodium). Severe electrolyte imbalances like this can indirectly affect fluid balance, which may influence blood pressure. The drug's official mechanism is not focused on blood pressure, though the noted side effect may influence it.


Q: Why do doctors recommend taking Selectra at a specific time of day?

A: Selectra tablets can technically be taken either in the morning or the evening. However, a specific time may be clinically advised to help manage common side effects. For example, taking it in the morning may be advised if a patient experiences insomnia, while taking it in the evening may be recommended if drowsiness is experienced.


Q: Are headaches a common side effect when you first start Selectra?

A: Yes, patient information from regulatory sources lists headaches as a common side effect when initiating treatment. These effects are generally described as mild and often lessen after a few weeks as the body adjusts to the medication.


Q: What are the concerns about using Selectra during pregnancy?

A: Official documents highlight that using Selectra during the Third Trimester may increase the risk of specific issues for the newborn, such as persistent pulmonary hypertension and signs of poor adaptation. The official position on use during pregnancy is that the therapeutic benefit to the mother must be determined to outweigh the potential risk to the infant.


Q: Can Selectra interact with herbal supplements like St. John's Wort?

A: Yes, the regulatory label specifically warns about co-administration with other serotonergic agents. Since St. John's Wort is a supplement with similar effects, taking it with Selectra increases the risk of a serious condition called Serotonin Syndrome.

How should Selectra be stored and disposed of?

Selectra (sertraline) tablets must be stored according to regulatory requirements to preserve product stability and ensure safety.

Official Storage Conditions

Requirement Official Regulatory Statement
Temperature Range Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), protected from excess heat.
Environmental Protection Store away from moisture and be protected from light.
Container Rules Keep this medication in the original container and keep the container tightly closed.
Child Safety Mandatory instruction to keep Selectra out of the reach and sight of children, utilizing safety caps where provided.

Official Disposal Instructions

Disposal must adhere to regulatory guidelines to prevent environmental release and unintended use. The recommended method for unused or expired Selectra is through a drug take-back program (e.g., pharmacy drop-off or mail-back envelopes).

If a take-back option is unavailable, the product should be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed bag before disposal in the household trash. Selectra is not on the list of medications recommended for immediate disposal by flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Selectra found in:

A-Z Index: